$CRVSCorvus Pharmaceuticals, Inc.

Active trials

• phase3Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphomarecruitingn=150
• phase1Safety, Tolerability, and Preliminary Efficacy of Soquelitinib in Participants With Moderate to Severe ADcompletedn=82
• phase2Study to Evaluate Soquelitinib in Participants With Moderate to Severe ADrecruitingn=200
• phase1A Dose Escalation Study Evaluating CPI-818 in Relapsed/Refractory T-Cell Lymphomaactive not recruitingn=151
• phase1CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancerscompletedn=117